These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1440400)

  • 21. [Two new drugs. Recombinant "human" erythropoietin (EPO: Erypo, Recormon)].
    Verwiebe R
    Internist (Berl); 1992 Apr; 33(4):279-81. PubMed ID: 1612854
    [No Abstract]   [Full Text] [Related]  

  • 22. [The after effect of r-HuEPO in treating anemic hemodialysis patients].
    Chu JQ
    Zhonghua Hu Li Za Zhi; 1994 Feb; 29(2):78-9. PubMed ID: 7788758
    [No Abstract]   [Full Text] [Related]  

  • 23. [Comparison of the efficacy and tolerance of recombinant human erythropoietin between intravenous and subcutaneous administration in chronic hemodialysis. Prospective multicenter study].
    Ruedin P; Stoerman C; Pechère-Bertschi A; Leski M
    Nephrologie; 1992; 13(2):87-92. PubMed ID: 1608502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of the evening i.v. administration of erythropoietin in haemodialyzed patients.
    Buemi M; Allegra A; Laganà A; Aloisi C; Privitera M; Morabito N; Frisina N
    Riv Eur Sci Med Farmacol; 1993; 15(5-6):195-7. PubMed ID: 7761669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erythropoietin and chronic renal failure.
    Drüeke T; Zins B; Naret C; Casadevall N; Goureau Y; Bererhi L; Zingraff J; Delons S; Kreis H; Varet B
    Nouv Rev Fr Hematol (1978); 1989; 31(2):97-8. PubMed ID: 2771635
    [No Abstract]   [Full Text] [Related]  

  • 26. Daily self-administered subcutaneous erythropoietin: benefits in haemodialysis patients.
    Granolleras C; Branger B; Deschodt G; Shaldon S; Nonnast-Daniel B; Pollok M
    Contrib Nephrol; 1990; 82():49-54. PubMed ID: 2093526
    [No Abstract]   [Full Text] [Related]  

  • 27. Recombinant human erythropoietin therapy in patients with rheumatoid arthritis with the anemia of chronic disease.
    Salvarani C; Lasagni D; Casali B; Macchioni P; Boiardi L; Rossi F; Rivasi P; Portioli I
    J Rheumatol; 1991 Aug; 18(8):1168-71. PubMed ID: 1941817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pain after subcutaneous injection of recombinant human erythropoietin: does Emla cream help?
    Morris KP; Hughes C; Hardy SP; Matthews JN; Coulthard MG
    Nephrol Dial Transplant; 1994; 9(9):1299-301. PubMed ID: 7816294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utilization of erythropoietin in the treatment of the anemia due to chronic renal failure.
    Drüeke T; Zins B; Naret C; Casadevall N; Goureau Y; Bererhi L; Peterlongo F; Castaigne JP; Zingraff J; Delons S
    Adv Nephrol Necker Hosp; 1989; 18():187-206. PubMed ID: 2493715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the factors in the cases resistant to recombinant human erythropoietin treatment.
    Suzuki M
    Contrib Nephrol; 1990; 82():65-71. PubMed ID: 2093529
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of the anaemia of chronic renal failure with recombinant human erythropoietin.
    Winearls CG
    Drugs; 1989 Sep; 38(3):342-5. PubMed ID: 2806134
    [No Abstract]   [Full Text] [Related]  

  • 32. Changes in determinants of blood rheology during treatment with haemodialysis and recombinant human erythropoietin.
    Koppensteiner R; Stockenhuber F; Jahn C; Balcke P; Minar E; Ehringer H
    BMJ; 1990 Jun; 300(6740):1626-7. PubMed ID: 2372642
    [No Abstract]   [Full Text] [Related]  

  • 33. Adverse events of subcutaneous recombinant human erythropoietin therapy: results of a controlled multicenter European study.
    Klinkmann H; Wieczorek L; Scigalla P
    Artif Organs; 1993 Apr; 17(4):219-25. PubMed ID: 8498900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is the use of subcutaneous epoetin beta once a week really equivalent to a more frequent administration of the same total dose?
    Andrulli S; D'Amico M; Locatelli F
    Nephrol Dial Transplant; 2001 Dec; 16(12):2439-40. PubMed ID: 11733645
    [No Abstract]   [Full Text] [Related]  

  • 35. Full results on risks of epoetin emerge 14 years after major dialysis study.
    Epstein K
    BMJ; 2012 May; 344():e3535. PubMed ID: 22619221
    [No Abstract]   [Full Text] [Related]  

  • 36. The ESA saga: a perfect storm of failed expectations and over-regulation.
    Wish J
    Nephrol News Issues; 2011 Aug; 25(9):13-4. PubMed ID: 21905525
    [No Abstract]   [Full Text] [Related]  

  • 37. Acute effect of erythropoietin on endothelin release in uremia.
    Nurol A; Bahattin A; Tolga K; Tekin A; Abdülkerim B
    Nephron; 1996; 72(4):728-9. PubMed ID: 8730461
    [No Abstract]   [Full Text] [Related]  

  • 38. Recombinant human erythropoietin and haemodialyser re-use.
    Dos Santos JP; Prata MM; Sousa FT; Barbas JV
    Nephron; 1990; 56(4):447-8. PubMed ID: 2080010
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and safety of recombinant human erythropoietin to prevent the anaemias of prematurity. European Randomized Multicenter Trial.
    Obladen M; Maier R; Segerer H; Grauel EL; Holland BM; Stewart G; Jorch G; Rabe H; Linderkamp O; Hoffmann HG
    Contrib Nephrol; 1991; 88():314-26. PubMed ID: 2040194
    [No Abstract]   [Full Text] [Related]  

  • 40. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders.
    Mittelman M; Floru S; Djaldetti M
    Blood; 1992 Aug; 80(3):841-3. PubMed ID: 1638033
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.